News Nanobiotix

Equities

NANO

FR0011341205

Market Closed - Euronext Paris Other stock markets 11:35:21 2024-05-10 am EDT			5-day change	1st Jan Change
6.37 ^EUR	+2.58%		+8.33%	-4.07%

Apr. 25	Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024
Apr. 24	Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nanobiotix : Notice RADSs agenda and summaries of resolutions – shareholders’ general meeting May 28, 2024	May. 07	PU
Nanobiotix : Notice ADSs agenda and summaries of resolutions – shareholders’ general meeting May 28, 2024	May. 07	PU
Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024	Apr. 25
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results	Apr. 24	GL
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024	Apr. 17	GL
Nanobiotix completes escalation portion of 2020-0123 study	Apr. 03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	Apr. 02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	Apr. 02	GL
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	Apr. 02	CI
Nanobiotix to Present at Upcoming Investor Conferences in March	Mar. 06	GL
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference	Jan. 31	GL
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference	Jan. 31	AQ
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	Jan. 30	MT
Nanobiotix: targets achieved for NANORAY-312	Jan. 30	CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen	Jan. 30	MT
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study	Jan. 29	GL
Nanobiotix: transfer of NBTXR3 rights in Asia	Dec. 27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nanobiotix

Equities

NANO

FR0011341205

Summary

Filters